中药新药的药代研究

摘要/Abstract

摘要： 开展中药药代研究是实现中药现代化的需要，国家药政管理部门积极鼓励在中药新药研发中开展药代研究，然而如何结合注册要求和中药特点开展中药新药的药代研究尚需在技术上进一步细化。本文从三个方面讨论中药新药的药代研究：(1)中药注册申报要求及药物研究技术指导原则涉及的中药药代研究；(2)中药药代动力学方法及研究实例；(3)对中药新药药代研究的思考。当前中药药代动力学在理论、方法、技术、应用上已取得长足发展，基本解决了对中药这类复杂混合物药物开展药代研究的技术难题，为开展中药新药（特别是含多种活性成分的复方中药新药）的药代研究打下基础。围绕中药新药研发需求，迫切需要加紧制定专门针对中药新药的药代动力学研究技术指导原则及药物相互作用研究技术指导原则，这将进一步提升我国中药新药研发的技术水平，并向人用药品注册技术要求国际协调会（ICH）贡献中国标准。

关键词: font-size:medium, ">药代动力学；药代性质药物相互作用；中药新药；中药注册

Abstract: Pharmacokinetic research plays a crucial role in advancing the modernization of Chinese herbal medicines. The Chinese National Medical Products Administration (NMPA) actively promotes the integration of pharmacokinetics research in the development of new herbal medicines. However， in order to effectively conduct pharmacokinetic research on investigational herbal medicines， further technical refinements are needed. These refinements must take into consideration the specific Chinese registration requirements for herbal medicines， as well as the unique characteristics of these medicines. In this Review， we explore the field of pharmacokinetics research on investigational herbal medicines from three perspectives. Firstly， we examine the Chinese registration requirements for herbal medicines， as well as herbalmedicinerelated recommendations that are outlined in the NMPA′s pharmacokinetic and drugdrug interaction research guidelines. Secondly， we provide a description of the methodologies used to conduct pharmacokinetic research on herbal medicines， accompanied by relevant study examples. Lastly， we discuss how to conduct pharmacokinetic research in a rational manner during the development of new herbal medicines. Significant progress has been made in the theory， methodologies， techniques， and applications of pharmacokinetics for Chinese herbal medicines. The progress made in resolving the technical challenges associated with conducting pharmacokinetic research on complex herbal medicines has established a solid foundation for pharmacokinetic research that supports the development of new herbal medicines， particularly those prepared from combinations of multiple herbs. In order to expedite the development of new herbal medicines， there is an urgent need to formulate comprehensive guidelines for pharmacokinetic research and drug interaction research that are specifically applicable to investigational herbal medicines. This will greatly improve the technical standards in development of new herbal medicines and enable Chinese standards to contribute to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Key words: Pharmacokinetics, Pharmacokinetic drugdrug interaction, Investigational Chinese herbal medicines, Registration of Chinese herbal medicines

中图分类号:

R284
R969.1

李川, 杨军令, 程晨, 贾伟伟. 中药新药的药代研究[J]. 中国药物评价, 2023, 40(6): 457-459.

LI Chuan, YANG Jun-ling, CHENG Chen, JIA Wei-wei. Pharmacokinetic Research on Investigational Chinese Herbal Medicines[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2023, 40(6): 457-459.

参考文献

[1] 张伯礼. 中医抗疫的文化自信[J]. 红旗文稿， 2021， (6)：3740.
     [2] Ni LQ， Chen LL， Huang X， et al. Combating COVID19 with integrated traditional Chinese and Western medicine in China [J]. Acta Pharm Sin B， 2020， 10(7)：11491162.
     [3] 中华人民共和国第十二届全国人民代表大会常务委员会. 中华人民共和国中医药法[M]. 北京：中国中医药出版社， 2017.
     [4] 中华人民共和国第十三届全国人民代表大会常务委员会. 中华人民共和国药品管理法[M]. 北京：中国法治出版社， 2019.
     [5] 国家药品监督管理局.中药注册分类及申报资料要求[EB/OL].（20200928）[20230901] https：//www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20200928164311143.html
     [6] 国家药品监督管理局. 中药、天然药物注射剂基本技术要求[EB/OL].(20071206) [20230901]. https：//www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20071206120001186.html
     [7] 国家药品监督管理局. 药物非临床药代动力学研究技术指导原则[EB/OL].（20140513）[20230901]. https：//www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20140513120001448.html
     [8] 国家药品监督管理局. 药物毒代动力学研究技术指导原则[EB/OL].（20140513）[20230901]. https：//www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20140513120001448.html
     [9] 国家药品监督管理局. 中药新药临床研究一般原则[EB/OL].（20151103）[20230901]. https：//www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20151103120001444.html
     [10] 国家药品监督管理局药品评审中心. 药物相互作用研究技术指导原则[EB/OL].（20120515）[20230901].， https：//www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=e0293bfd34a7c44a93382776199101bb.
     [11] 李川. 中药多成分药代动力学研究：思路与方法[J]. 中国中药杂志， 2017， 42(4)：607617.
     [12] 李川，程晨，贾伟伟，等. 中药多成分药代动力学：发现与中药安全性和有效性关联的物质并揭示其药代特征[J]. 药学学报， 2021， 56(9)：24262446.
     [13] 李川. 第十五章中药药代动力学及其研究方法. 药代动力学理论与实践（王广基主编）[M]. 北京：人民卫生出版社， 2022：320335.
     [14] Li C， Jia WW， Yang JL， et al. Multicompound and drugcombination pharmacokinetic research on Chinese herbal medicines[J]. Acta Pharmacol Sin， 2022， 43(12)：30803095.
     [15] Lan XF， Olajide OE， Du FF， et al. Pharmacokineticsbased identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule[J]. Acta Pharmacol Sin， 2021， 42(12)：21552172.
     [16] Omar HR， Komarova I， ElGhonemi M， et al. Licorice abuse： time to send a warning message[J]. Ther Adv Endocrinol Metab， 2012， 3(4)：125138.
     [17] Pintusophon S， Niu W， Duan XN， et al. Intravenous formulation of Panax notoginseng root extract： human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions[J]. Acta Pharmacol Sin， 2019， 40(10)：13511363.
     [18] Bailey DG， Spence JD， Munoz C， et al. Interaction of citrus juices with felodipine and nifedipine[J]. Lancet， 1991， 337(8736)：268269.
     [19] Bailey DG， Arnold JMO， Bend JR， et al. Grapefruit juicefelodipine interaction： reproducibility and characterization with the extended release drug formulation[J]. Br J Clin Pharmacol， 1995， 40(2)：135140.
     [20] Ruschitzka F， Meier PJ， Turina M， et al. Acute heart transplant rejection due to Saint John′s wort[J]. Lancet， 2000， 355(9203)：548549.
     [21] Breidenbach T， Kliem V， Burg M， et al. Profound drop of cyclosporine a whole blood trough levels caused by St. John′s wort (Hypericum perforatum) [J]. Transplantation， 2000， 69(10)：22292230.
     [22] Malati CY， Robertson SM， Hunt JD， et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and Pglycoprotein (Pgp) activity in healthy participants[J]. J Clin Pharmacol， 2012， 52(6)：932939.
     [23] Gurley BJ， Gardner SF， Hubbard MA， et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly： St John's wort， garlic oil， Panax ginseng and Ginkgo biloba[J]. Drug Aging， 2005， 22(6)：525539.
     [24] Jiang RR， Dong JJ， Li XX， et al. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenosideperpetrated herbdrug interactions on OATP1B3[J]. Br J Pharmacol， 2015， 172(4)：10591073.
     [25] Zeng X， Deng YH， Feng Y， et al. Pharmacokinetics and safety of ginsenoside Rd following a single or multiple intravenous dose in healthy Chinese volunteers[J]. J Clin Pharmacol， 2010， 50(3)：285292.
     [26] Li J， Olaleye OE， Yu X， et al. High degree of pharmacokinetic compatibility exists between the fiveherb medicine XueBiJing and antibiotics comedicated in sepsis care[J]. Acta Pharm Sin， 2019， 9(5)：10351049.
     [27] Song YL， Yao C， Yao YM， et al. XueBiJing injection versus placebo for critically ill patients with severe communityacquired pneumonia： a randomized controlled trial[J]. Crit Care Med， 2019， 47(9)：e735743.
     [28] Liu SQ， Yao C， Xie JF， et al. Effect of Xuebijing injection on 28day mortality in patients with sepsis： the EXITSEP randomized clinical trial[J]. JAMA Intern Med， 2023， 183(7)：647655.
     [29] Dong JJ， Olaleye OE， Jiang RR， et al. Glycyrrhizin has a high likelihood to be a victim of drugdrug interactions mediated by hepatic OATP1B1/1B3[J]. Br J Pharmacol， 2018， 175(17)：34863503.